Mer­ck­'s $500M bet on Sin­ga­pore leads to new man­u­fac­tur­ing sites mak­ing Keytru­da, Gar­dasil and fu­ture in­halers

In a boost to its Asia Pa­cif­ic re­gion­al head­quar­ters in Sin­ga­pore, Mer­ck has opened a new sec­ondary pack­ag­ing fa­cil­i­ty and bro­ken ground on a sep­a­rate fa­cil­i­ty that will man­u­fac­ture next-gen­er­a­tion in­halers.

The two man­u­fac­tur­ing sites are part of a $500 mil­lion in­vest­ment to ex­pand pro­duc­tion of med­i­cines and vac­cines in Sin­ga­pore over five years, dat­ing back to 2020.

As Fer­nan­do Otero, as­so­ciate vice pres­i­dent, MSD Man­u­fac­tur­ing Di­vi­sion, Sin­ga­pore, put it, Mer­ck sees the coun­try “as a strate­gic node in our com­pa­ny’s glob­al man­u­fac­tur­ing net­work with a fo­cus on pro­duc­ing in­no­v­a­tive med­i­cines to treat chron­ic dis­eases and can­cer as well as vac­cines that pre­vent in­fec­tious dis­eases for pa­tients liv­ing in Sin­ga­pore and through­out the Asia Pa­cif­ic re­gion and be­yond.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER